Drug intelligence / Profile preview

GEN-725 + dositinib mesylate

Development stage: Unknown
Lead developer: Genuine Biotech
Modality: Small Molecules
Administration: Oral

Overview

GEN-725 + dositinib mesylate is an investigational combination therapy developed by Henan Genuine Biotech Co., Ltd. for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations. Dositinib mesylate is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively targets both sensitizing mutations and the T790M resistance mutation while sparing wild-type EGFR. GEN-725 is a novel small molecule being evaluated in combination with dositinib to potentially enhance therapeutic efficacy or overcome resistance mechanisms in patients who have progressed on or are candidates for EGFR-targeted therapy. The combination is currently undergoing Phase I/IIa clinical evaluation to assess its safety, tolerability, and preliminary anti-tumor activity.

Other names: GEN-725 + dositinib

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)DCK (Deoxycytidine kinase)

Beyond the preview

Go deeper on GEN-725 + dositinib mesylate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GEN-725 + dositinib mesylate.

Explore the full profile